{"id":"NCT00576628","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Subcutaneous C.E.R.A. for the Treatment of Anemia in Pre-Dialysis Patients.","officialTitle":"A Single Arm Open Label Multicentre Study to Assess the Efficacy, Safety and Tolerability of Monthly Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anaemia in Pre-dialysis Patients, Not Currently Treated With ESA","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2010-03","completion":"2010-03","firstPosted":"2007-12-19","resultsPosted":"2016-11-30","lastUpdate":"2016-11-30"},"enrollment":133,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia"],"interventions":[{"type":"DRUG","name":"methoxy polyethylene glycol-epoetin beta [C.E.R.A.]","otherNames":[]}],"arms":[{"label":"C.E.R.A","type":"EXPERIMENTAL"}],"summary":"This single arm study will assess the efficacy, safety and tolerability of subcutaneous C.E.R.A. for correction of anemia and maintenance of hemoglobin levels in patients with chronic kidney disease who are not on dialysis and are not treated with ESA. Eligible patients will receive C.E.R.A. by monthly subcutaneous injections, dependent on body weight (with a recommended starting dose of 1.2 micrograms/kg). The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Mean Change in Hb Concentration g/dL Between Baseline and the Efficacy Evaluation Period","timeFrame":"Baseline (Week 0) and from Week 29 to Week 36","effectByArm":[{"arm":"C.E.R.A","deltaMin":1.75,"sd":1.09}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":19,"countries":["Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":125},"commonTop":["Hypertension","Influenza","Asthenia","Hyperkalaemia","Blood Pressure Increased"]}}